Fujisawa Protopic
Executive Summary
Review deadline extended three months beyond September user-fee date for tacrolimus ointment for the short- and long-term treatment of signs and symptoms of atopic dermatitis. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee will review the product Nov. 16. A meeting had been scheduled for Aug. 16